Abstract:Cancer cells avidly take up glucose and convert it to lactate while eschewing oxidative phosphorylation. This phenomenon is critical for maximal tumorigenicity, and is in part explained by the almost universal reversion of tumours to the embryonic form of pyruvate kinase, PKM2. Here, David et al. now show that aberrant expression of the splicing factors PTB, hnRNPA1 and hnRNPA2, which are themselves regulated by the c-Myc oncogene, is responsible for the PKM1 to PKM2 switch in cancer. This work adds to our understanding of alternative splicing and its role in cancer cell growth. Expression of the embryonic M2 isoform of pyruvate kinase (PKM2) by tumour cells promotes aerobic glycolysis, whereas the normal adult isoform, PKM1, promotes oxidative phosphorylation. Expression of these isoforms is regulated by alternative splicing; here, aberrant expression of three heterogeneous nuclear ribonucleoprotein splicing factors, which are themselves regulated by the c-Myc oncogene, is shown to be responsible for the M1 to M2 switch in cancer. When oxygen is abundant, quiescent cells efficiently extract energy from glucose primarily by oxidative phosphorylation, whereas under the same conditions tumour cells consume glucose more avidly, converting it to lactate. This long-observed phenomenon is known as aerobic glycolysis1, and is important for cell growth2,3. Because aerobic glycolysis is only useful to growing cells, it is tightly regulated in a proliferation-linked manner4. In mammals, this is partly achieved through control of pyruvate kinase isoform expression. The embryonic pyruvate kinase isoform, PKM2, is almost universally re-expressed in cancer2, and promotes aerobic glycolysis, whereas the adult isoform, PKM1, promotes oxidative phosphorylation2. These two isoforms result from mutually exclusive alternative splicing of the PKM pre-mRNA, reflecting inclusion of either exon 9 (PKM1) or exon 10 (PKM2). Here we show that three heterogeneous nuclear ribonucleoprotein (hnRNP) proteins, polypyrimidine tract binding protein (PTB, also known as hnRNPI), hnRNPA1 and hnRNPA2, bind repressively to sequences flanking exon 9, resulting in exon 10 inclusion. We also demonstrate that the oncogenic transcription factor c-Myc upregulates transcription of PTB, hnRNPA1 and hnRNPA2, ensuring a high PKM2/PKM1 ratio. Establishing a relevance to cancer, we show that human gliomas overexpress c-Myc, PTB, hnRNPA1 and hnRNPA2 in a manner that correlates with PKM2 expression. Our results thus define a pathway that regulates an alternative splicing event required for tumour cell proliferation.

A Splicing Switch from Ketohexokinase-C to Ketohexokinase-a Drives Hepatocellular Carcinoma Formation

Turning on a Fuel Switch of Cancer: Hnrnp Proteins Regulate Alternative Splicing of Pyruvate Kinase Mrna

Intron Retention of DDX39A Driven by SNRPD2 is a Crucial Splicing Axis for Oncogenic MYC/Spliceosome Program in Hepatocellular Carcinoma

Mutually exclusive acetylation and ubiquitylation of the splicing factor SRSF5 control tumor growth

CRISPR/Cas9 Screens Reveal that Hexokinase 2 Enhances Cancer Stemness and Tumorigenicity by Activating the ACSL4‐Fatty Acid β‐Oxidation Pathway

Splicing Regulator p54nrb/Non–POU Domain–Containing Octamer-Binding Protein Enhances Carcinogenesis Through Oncogenic Isoform Switch of MYC Box–Dependent Interacting Protein 1 in Hepatocellular Carcinoma

KHK-A promotes fructose-dependent colorectal cancer liver metastasis by facilitating the phosphorylation and translocation of PKM2

Fructose and Fructose Kinase in Cancer and Other Pathologies

Fructose metabolism in tumor endothelial cells promotes angiogenesis by activating AMPK signaling and mitochondrial respiration.

HIF-1α Mediates Functional Switching of TGF-Β Signaling by Regulating the PKM Mrna Splicing and Metabolic Reprogramming in Non-Small Cell Lung Cancer

A novel MYC-ZNF706-SLC7A11 regulatory circuit contributes to cancer progression and redox balance in human hepatocellular carcinoma

Metabolic Enzyme SLC27A5 Regulates PIP4K2A pre‐mRNA Splicing as a Noncanonical Mechanism to Suppress Hepatocellular Carcinoma Metastasis

Stabilization of AMPK/PFKL/RPIA in the Glycolytic Bodies Transduces IL6/STAT3 Signal in Hepatocarcinogenesis

Fructose induced KHK-C can increase ER stress independent of its effect on lipogenesis to drive liver disease in diet-induced and genetic models of NAFLD

PTBP1 promotes the progression of hepatocellular carcinoma by enhancing the oncogenic splicing switch of FGFR2

The aberrant upregulation of exon 10-inclusive SREK1 through SRSF10 acts as an oncogenic driver in human hepatocellular carcinoma

HnRNP Proteins Controlled by C-Myc Deregulate Pyruvate Kinase Mrna Splicing in Cancer.

HSF1: a Mediator in Metabolic Alteration of Hepatocellular Carcinoma Cells in Cross-Talking with Tumor-Associated Macrophages.

USP39 Promotes Hepatocellular Carcinogenesis Through Regulating Alternative Splicing in Cooperation with SRSF6/HNRNPC

Correction: Corrigendum: A splicing switch from ketohexokinase-C to ketohexokinase-A drives hepatocellular carcinoma formation

An inflammatory-CCRK circuitry drives mTORC1-dependent metabolic and immunosuppressive reprogramming in obesity-associated hepatocellular carcinoma